VERACYTE, INC. (NASDAQ:VCYT) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Item 5.02 Departure of Directors or Certain Officers; Election of
Directors; Appointment of Certain Officers; Compensatory
Arrangements of Certain Officers.
that Kevin K. Gordon, former chief operating officer of Quintiles
Transnational Holdings Inc. (NYSE: Q), has been elected to the
Companys board of directors, effective December 12, 2016. Mr.
Gordon will also serve as a member of the Audit Committee of the
Board of Directors. Mr. Gordon is a Class III director and his term
will expire at the 2019 Annual Meeting of Stockholders. Brian G.
Atwood, who has served as director and chairman since the Companys
founding, has elected to step down from the board, effective
December 12, 2016. Effective December 12, 2016, Bonnie H. Anderson,
the Companys president and chief executive officer, has assumed the
additional role of chairman of the board and John L. Bishop will
become the lead independent director.
chief operating officer of Quintiles Transnational Holdings Inc.,
from October 2015 until its merger with IMS Health in October
2016. From July 2010 to October 2015, Mr. Gordon served as
executive vice president and chief financial officer of
Quintiles. From March 2007 to January 2010, he served as
executive vice president and chief financial officer of Teleflex
Incorporated. From January 1997 to March 2007, he held various
senior corporate development positions at Teleflex Incorporated.
From March 1992 to January 1997, he held various senior finance
positions at Package Machinery Company. From August 1984 to March
1992, he held various finance positions at KPMG. Mr. Gordon holds
a B.S. in Accounting from the University of Connecticut.
entitled to the same cash and equity compensation paid by the
Company to each of its non-employee directors, as described in
the Company’s proxy statement for its 2016 Annual Meeting of
Stockholders filed on May 6, 2016. The Company has not entered
into any transactions with Mr. Gordon that would require
disclosure to Item 404(a) of Regulation S-K under the Securities
Exchange Act of 1934.
to serve as lead independent director, which amount will be
prorated for 2016.
changes is attached hereto as Exhibit 99.1 and is incorporated by
reference herein.
|
Exhibit No.
|
Description
|
||
|
|
|
|
|
|
99.1
|
|
Press release issued by Veracyte, Inc. dated December 13,
2016. |
About VERACYTE, INC. (NASDAQ:VCYT)
Veracyte, Inc. is a genomic diagnostics company. The Company uses genomic technology to resolve diagnostic ambiguity. It targets diseases in which patients undergo invasive diagnostic procedures. Its products combine genomic technology, clinical science and machine learning. The Company commercializes over three genomic tests, which are transforming the diagnosis of thyroid cancer, lung cancer and idiopathic pulmonary fibrosis. The Company’s commercial solution, the Afirma Thyroid fine needle aspiration (FNA) Analysis, centers on the Afirma Gene Expression Classifier (GEC). The Afirma GEC is offered directly or as part of a solution that also includes cytopathology. The Company operates in the pulmonology diagnostics market. It offers Percepta Bronchial Genomic Classifier, a genomic test to resolve ambiguity in lung cancer diagnosis. It also offers the Envisia Genomic Classifier, which is designed to help in the assessment of patients suspected to have idiopathic pulmonary fibrosis. VERACYTE, INC. (NASDAQ:VCYT) Recent Trading Information
VERACYTE, INC. (NASDAQ:VCYT) closed its last trading session up +0.01 at 7.40 with 160,926 shares trading hands.